Holocene Advisors Believes Merck’s Proposed Offer of $180 Per Share for Acceleron Significantly Undervalues Company
- Tech lifts S&P 500, Nasdaq amid inflation, China growth worries
- Zillow (ZG) Stock Falls on Report Company Paused Home Purchases due to High Demand, a Temporary Halt Yields a Chance for Competitors Says Analyst
- Oil prices ease off highs as U.S. factory data weighs on market
- Chip Shortages are Increasingly Becoming a New Bearish Risk, Inflation Bearish for Consumer Electronics - TFI's Kuo
- Walt Disney (DIS) Stock Slips as Barclays Downgrades Amid Disney+ Growth Slowdown
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Long-term Holder Does Not Intend to Tender Shares into Merck’s Offer
NEW YORK--(BUSINESS WIRE)-- Holocene Advisors, LP (“Holocene”), a fundamental investment management firm and significant shareholder of Acceleron Pharma Inc. (Nasdaq: XLRN) (“Acceleron” or the “Company”), today announced that it does not intend to tender its shares into Merck & Co.’s (NYSE: MRK) proposed $180 per share offer for the Company announced on September 30, 2021.
Holocene stated the following:
“As a large shareholder in Acceleron, we believe the Company’s management team has done an excellent job of creating value for shareholders; however, a transaction now, at this price, is not compelling. While Merck ultimately could be an attractive partner for Acceleron, we believe its $180 per share offer significantly undervalues the Company based on a discounted cash flow analysis and recent comparable transactions, and does not compensate XLRN shareholders adequately, given Acceleron’s strong pipeline and attractive long-term business prospects.
“Acceleron’s lead pipeline asset, sotatercept, has the potential to be a foundational and disease-modifying agent for the treatment of pulmonary arterial hypertension (PAH) and generate billions of dollars in sales. Additionally, royalties on Reblozyl, a potential blockbuster drug to treat anemia in patients with myelodysplastic syndromes (MDS), provide further valuation support as well as a meaningful source of cash flow to fund Acceleron’s expanding novel pipeline. We believe that Acceleron’s value will continue to significantly increase over time as more clinical data is released and the Company’s assets are further derisked.
“While we normally do not comment on such matters, we believe that if this transaction is allowed to proceed on these terms, XLRN shareholders would be deprived of substantial value.”
About Holocene Advisors, LP
Holocene is an investment management firm registered as an investment advisor with the Securities and Exchange Commission (the “SEC”) that operates out of New York City. Holocene pursues a sector-diversified, beta-neutral long/short equity strategy with a focus on alpha generation through deep, fundamental research and financial modeling, conducted by sector-focused investment teams. Holocene manages significant holdings in the Healthcare space, including biopharmaceutical companies.
Additional Information and Cautionary Statement Regarding Forward-Looking Information
This press release is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any shares of the common stock of Acceleron or any other securities. This press release contains statements that are “forward-looking statements” within the meaning of the Securities Exchange Act of 1934, as amended. All statements contained in this press release, other than statements of historical facts, are “forward-looking statements” for purposes of these provisions. Statements made in this press release are qualified by the cautionary statements made in this press release. Although Holocene believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Holocene, Merck or Acceleron, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Holocene does not intend and does not assume any obligation, to update any of the statements included in this press release. An investment in common stock issued by Acceleron is subject to the risks described in its yearly, quarterly and periodic filings with the SEC, which are or will be available over the Internet at the SEC’s website at http://www.sec.gov.
Jonathan Gasthalter/Nathaniel Garnick
Gasthalter & Co.
Source: Holocene Advisors, LP
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- SEC to Allow First Ever Bitcoin (BTC) ETF - Report
- Chart Industries (GTLS) Announces MOU with Ionada for Carbon Capture Utilization and Storage (CCUS) Projects in the Shipping Industry
- XORTX Therapeutics Inc (XRTX) Closes $12M Public Offering
Create E-mail Alert Related CategoriesBusiness Wire, Press Releases
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!